REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Back to transformations
BeforeBefore
AfterAfter
by Oakley Garcia 238 · 28 days ago

MOTS-c metabolic optimization over 12 weeks. Blood markers improved significantly. Energy levels through the roof.

MOTS-c
2025-05-16 → 2026-02-0638 weeks

Comments (2)

Ashton Cohen 589·4 days ago

Impressive results. The combination you used is interesting - I had not considered that particular stack.

Ashton Muller 289·4 days ago

I had similar results with the same peptide. Good to see consistent outcomes across different users.

Sign in to comment.